Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels

Choi, Hyo Jung; Seo, Eun Hyun; Yi, Dahyun; Sohn, Bo Kyung; Choe, Young Min; Byun, Min Soo; Lee, Jong Min; Woo, Jong Inn; Lee, Dong Hoon

doi:10.1016/j.jagp.2015.06.004

Cited by 20 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since SR-BI has already been identified as a major receptor for HDL (with their major apolipoprotein [apo] A-I) as well as for the earlier-described LCM/ND nanoemulsion , this multitasking lipid nanoemulsion can arguably serve as a targeted, apoA-I-based, (SR-BI mediated) therapeutic agent for Alzheimer’s disease [ 56 , 58 , 59 , 60 ] (cf. [ 61 , 62 , 63 , 64 , 65 , 66 , 67 ]).…”

Section: Targeted Delivery (Of Drugs Including Antibody Therapeutimentioning

confidence: 99%

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting

D'Arrigo

2017

Medical Sciences

View full text Add to dashboard Cite

Owing to the complexity of neurodegenerative diseases, multiple cellular types need to be targeted simultaneously in order for a given therapy to demonstrate any major effectiveness. Ultrasound-sensitive coated microbubbles (in a targeted nanoemulsion) are available. Versatile small-molecule drug(s) targeting multiple pathways of Alzheimer’s disease pathogenesis are known. By incorporating such drug(s) into the targeted lipid-coated microbubble/nanoparticle-derived (LCM/ND) lipid nanoemulsion type, one obtains a multitasking combination therapeutic for translational medicine. This multitasking therapeutic targets cell-surface scavenger receptors (mainly scavenger receptor class B type I (SR-BI)), making it possible for various Alzheimer’s-related cell types to be simultaneously sought for localized drug treatment in vivo. Besides targeting cell-surface SR-BI, the proposed LCM/ND-nanoemulsion combination therapeutic(s) include a characteristic lipid-coated microbubble (LCM) subpopulation (i.e., a stable LCM suspension); such LCM substantially reduce the acoustic power levels needed for accomplishing temporary noninvasive (transcranial) ultrasound treatment, or sonoporation, if additionally desired for the Alzheimer’s patient.

show abstract

Section: Targeted Delivery (Of Drugs Including Antibody Therapeutimentioning

confidence: 99%

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting

D'Arrigo

2017

Medical Sciences

View full text Add to dashboard Cite

show abstract

“…(LCM/ND) nanoemulsion (see below), this multitasking lipid nanoemulsion can arguably serve as a targeted, apoA-I-based, (SR-BI mediated) therapeutic agent for common (late-onset) dementias [2,29,31,[33][34][35][36][37] (cf. [38][39][40][41][42][43]).…”

Section: Endothelial Dysfunction As a Therapeutic Target For Cognitivmentioning

confidence: 99%

NANOTHERAPY TO DELAY COGNITIVE IMPAIRMENT: USING COLLOIDAL NANOCARRIERS TO BLOCK AMYLOID-β-INDUCED DAMAGE IN BRAIN CELL MEMBRANES

D'Arrigo¹

2019

SDRP-JNMS

View full text Add to dashboard Cite

Background: Numerous published studies indicate that microvascular endothelial dysfunction precedes cognitive decline in Alzheimer's disease, and that preservation of a healthy cerebrovascular endothelium can be an important therapeutic target. Methods: By incorporating appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combination therapeutic which targets certain cell-surface scavenger receptors, mainly class B type I (i.e., SR-BI), and crosses the blood-brain barrier. Documented similarities in lipid composition between high-density lipoproteins (HDL) and the biomimetic (nanoemulsion) nanocarrier particles can partially simulate or mimic the known heterogeneity (i.e., subpopulations or subspecies) of HDL particles. Moreover, the above-described type BI scavenger receptor (i.e., either SR-BI (rodent) and/or CLA-1 (human) orthologs) has been shown to be a multifunctional receptor able to bind a broad variety of ligands, including HDL and chylomicron remnants. Results: Such colloidal-nanocarrier targeting allows for various Alzheimer's-related cell types to be simultaneously searched out, in vivo, for localized drug treatment. Using various lipids and their mixtures to form self-assembled non-lamellar nanostructures, it has continually been reported possible to successfully obtain stable colloidal dispersions of (liquid-crystalline) lipid cubic phases with well-defined particle size and morphology. In particular, within the range of self-assembled phases in model surfactant-like lipid systems, various investigators further emphasize that monglyceride-based lyotropic liquid-crystalline phases are relatively unique owing to their rich polymorphism in water and potential application as drug nanocarriers. Conclusion: This (colloidal-nanocarrier) in vivo targeting advantage may be particularly important for repurposing an FDA-approved drug, especially one which has shown the added ability to restore some cognitive functions in certain animals models of Alzheimer's disease (e.g., the anticancer drug bexarotene). Bexarotene (and several analogs or other candidate-repurposing drugs) up to now, by itself (i.e., without nanocarrier), displayed poor CNS penetration in human subjects.

show abstract

“…Since SR-BI has already been identified as a major receptor for HDL (with their major apolipoprotein (apo)A-I) as well as for the recently reviewed [1, 2+ "lipidcoated microbubble/nanoparticle-derived" (LCM/ND) nanoemulsion (see below), this multitasking lipid nanoemulsion can arguably serve as a targeted, apoA-I-based, (SR-BI mediated) therapeutic agent for common (late-onset) dementias [2,33,[38][39][40] (cf. [41][42][43][44][45][46][47]).…”

Section: Endothelial Dysfunction and Targeted Treatment For Early Dementioning

confidence: 99%

Treating Dementia Early: Limiting Cellular Damage in Brain Tissue

D'Arrigo¹

2018

obm geriatr

View full text Add to dashboard Cite

Much evidence has been published which indicates that microvascular endothelial dysfunction, due to cerebrovascular risk factors (e.g., atherosclerosis, hypertension, obesity, diabetes, smoking, aging), precedes cognitive decline in Alzheimer's disease and contributes to its pathogenesis. By incorporating appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combination therapeutic which targets certain cellsurface scavenger receptors, and crosses the blood-brain barrier (BBB). Such targeting allows for various Alzheimer's-related cell types to be simultaneously searched out, in vivo, for localized drug treatment. This in vivo targeting advantage may be particularly important for repurposing FDA-approved drug(s), especially one which has shown the added ability to restore some cognitive functions in certain animal models of Alzheimer's disease.

show abstract

Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels

Cited by 20 publications

References 34 publications

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting

NANOTHERAPY TO DELAY COGNITIVE IMPAIRMENT: USING COLLOIDAL NANOCARRIERS TO BLOCK AMYLOID-β-INDUCED DAMAGE IN BRAIN CELL MEMBRANES

Treating Dementia Early: Limiting Cellular Damage in Brain Tissue

Contact Info

Product

Resources

About